Search
Displaying 141–150 of 693 for “retinal diseases”
-
Second Sight Agrees to Merger to Maintain Retinal and Cortical Prostheses Programs
Research NewsCompany has been unable to meet revenue goals for the Argus II®
-
jCyte Reports Results for Phase 1/2a Clinical Trial for Retinal-Cell Treatment
Research NewsSome participants reported increased light sensitivity, improved color vision, better mobility, and improved reading ability.
-
Opus Genetics Reports Promising Early Results from BEST1 Gene Therapy Trial
Research NewsFirst patient shows vision improvements with a good safety profile.
-
Seeing Science Through a Cellular Lens
Beacon StoriesOn International Day of Women and Girls in Science, meet Jillian Pearring, PhD, a Foundation Fighting Blindness–funded researcher whose work on photoreceptors and retinitis pigmentosa is helping advance treatments and cures for blinding diseases.
-
Foundation Fighting Blindness Provides Public Access to Data From its RUSH2A Natural History Study
Foundation NewsRUSH2A has captured extensive data over four years from patients with USH2A mutations causing non-syndromic retinitis pigmentosa and Usher syndrome type 2A.
-
After a review by our Scientific Advisory Board (SAB), three key research gaps were identified: models to study retinal diseases, understanding how the immune system reacts, and finding biomarkers that can predict disease progression and help guide treatment decisions.
-
ARVO 2016: What Does It Take to Develop a Stem-Cell Therapy for the Retina?
Research NewsThere are innumerable considerations for researchers developing therapies.
-
Orphan Drugs Get Special Treatment
Research NewsFor developers of treatments for rare diseases — including inherited retinal conditions — “orphan” status provides valuable benefits, such as tax incentives, access to special research grants and assistance with clinical trial design.
-
Stargardt Disease Research Advances
Research NewsRecent developments in research on Stargardt disease.
-
The fiscal year 2025-2029 Science Strategic Plan is developed with a single, overarching goal: To drive research projects and activities to overcome barriers to translating preclinical research into clinical trials for individuals affected by inherited retinal diseases and dry AMD.
